18.10.2014 17:58 single arm, single agent, phase II trial of neratinib, an irreversible ERBB2 inhibitor, in metastatic ERBB2 mutant, HER2 negative breast cancer (PUMA-NER-1202)

EORTC-Studien: Brustkrebs

22922 Mamma  
10853 Die Bestrahlung der Brust nach brusterhaltend operiertem DCIS vermindert sowohl die Rate intramammärer DCIS-Rezidive als auch invasiver Rezidive signifikant!
1324 A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
1324 10085p Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study.
1307 A phase 3 randomized trial of Niraparib versus Physician's choice in patients with germline BRCA mutation and previously treated breast cancer
75111 Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH/PHM: an open-label multicentre randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group
90091 TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial)
10112 A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.
10085 Clinical and biological characterization of Male Breast Cancer : an international retrospective EORTC, BIG and NABCG intergroup study (for the prospective part, please refer to 10085p)
22085 A randomized phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast.
10071 A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
90061 Multicenter parallel phase II trial of BI 2536 administrered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions (NOCI)
10055 Phase III Trial Evaluating the role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx, Doxil) for Women (age 66 year or older) with Endocrine Non-responsive Breast Cancer who are NOT suitable for being Offered a "Standard Chemotherapy Regimen".
10054 A phase I-II study of Lapatinib and Docetaxel as neoadjuvant treatment for locally advanced breast cancer.
10041 MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid Chemo Therapy): A prospective, randomized study comparing the 70-gene signature with the common clinicpathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes"
10053 Pharmacokinetics study of combined treatment Lapatinib and Tamoxifen in advanced/metastatic breast cancer
22051 Selective Use of Postoperative Radiotherapy AftEr MastectOmy (SUPREMO)
10031 A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer tamoxifen versus ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (SOFT).
16023 Phase I study of lonafarnib (SCH66336) in combination with Herceptin plus paclitaxel in HER-2 neu overexpressing breast cancer.
10021 An EORTC randomized, double blind, placebo controlled, Phase II multi-center trial of anastrozole (Arimidex) in combination with ZD1839 (Irissa(R)) or placebo in patients with advanced breast cancer.
10012 An IDBBC single arm phase II trial evaluating the activity of Iressa (ZD 1839) in metastatic breast cancer patients pretreated with an antiestrogen and a nonsteroidal aromatase inhibitor (anastrozole or letrozole).
10002 A survey of the Breast International Group (B.I.G.) to assess the attitude of patients aged less than 35 years, with early breast cancer, toward the risk of loss of fertility related to adjuvant therapies.
10001 A randomized phase II-III trial evaluating the efficacy of capecitabine and vinorelbine in anthracycline and taxane pre-treated metastatic breast cancer.
10011 A Randomized, Three-arm, Multicenter Comparison of 1 year and 2 years of Herceptin Versus no Herceptin in Women with HER2 Positive Primary Breast Cancer who have Completed Adjuvant Chemotherapy.
10995 A Phase II Study of CMF in Combination with Anti c-erbB2 antibody (HerceptinR) in Women with c-erbB2 positive Metastatic Breast Cancer
10974 LAMANOMA: Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: a randomized phase III study.
10003 An EORTC-BG-IDBBC/ECSG phase II study evaluating the role of the multi-drug resistance (MDR) reversor, R101933, in patients with taxane refractory metastatic breast cancer.
10994 First prospective Intergroup Translational Research Trial assessing the potential predictive value of p53 using a functional assay in yeast in patients with locally advanced/inflammatory or large operable breast cancer prospectively randomised to a taxane versus a non taxane regimen.
10981 After Mapping of the Axilla:Radiotherapy Or Surgery AMAROS
10963 PEAT-Perioperative Endocrine Adjuvant Treatment- "A double blind phase III clinical trial to compare the effects of a preoperatively administered single dose of "Faslodex" (long acting ICI 182.780) with placebo on tumor recurrence in pre- and postmenopausal women treated for operable first primary cancer"
10992 Habits Hormonal replacement therapy after breast cancer diagnosis - is it safe? Protocol for randomized clinical study concerning hormonal replacement therapy (HRT) after previous radical breast cancer treatment.
10983 A Phase III randomized double blind study of letrozole versus placebo in women with primary breast cancer completing five or more years of adjuvant Tamoxifen (NCIC CTG MA.17, EORTC study 10983)
16001 Phase II study of oxaliplatin single agent in patients with metastatics breast cancer after failure of Anthracycline/Taxanes based chemotherapy. EORTC protocol 16001.
10993 A randomised phase II study of two different schedules of Caelyx in metastatic breast cancer
10991 EORTC-IDDBC Phase I study of Capecitabine (Xeloda) in combination with Epirubicin and cyclophosphamide (CEX) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
05971 A multicenter randomized trial, with direct individual benefit, to determine the optimal circadian time of Vinorelbine administration combined with chronomodulated infusion of 5-Fluorouracil in previously treated patients with metastatic breast cancer.
10967 Randomized double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant Tamoxifen for 2-3 years, comparing subsequent adjuvant Exemestane treatment with further Tamoxifen.
10961 Doxorubicin / Taxol as first line chemotherapy in advanced breast cancer : a randomized study versus standard Doxorubicin / Cyclophosphamide combination regimen. A phase II study leading to a phase III.
22922 Phase III randomized trial investigating the role of internal mammary and medial supraclavicular (IM-MS) lymph node chain irradiation in stage I-III breast cancer (Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Breast Cancer Cooperative Group EORTC 22922/10925)
10951 Randomized phase II and III study in first line hormonal treatment for metastatic breast cancer with Exemestane or Tamoxifen in postmenopausal patients
10932 Phase III study of evaluation of breast irradiation in early stage, low risk breast cancer patients after complete tumor excision (Joint study of the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Cooperative Group)
04951 Phase II first line chemotherapy study with docetaxel (taxotere - RP56976) in patients with metastatic breast cancer
15931 An international field study of the reliability and validity of the EORTC QLQ-C30 (v. 3.0) and a disease-specific questionnaire module (the QLQ-BR23) in assessing the quality of life of patients with breast cancer
10941 Open, non-randomized parallel-group, phase II study of Liarozole Fumarate in patients with advanced breast cancer
10924 Double-blind randomized phase III multicentre trial comparing the effect of oral pamidronate (CGP 23339A - Aredia) with placebo in patients with newly diagnosed bone metastases from breast cancer
10920 An EORTC randomized phase III trial aiming at defining the role of short-term intensive chemotherapy at the time of isolated loco-regional relapse in breast cancer patients
04931 A phase II first line chemotherapy study with docetaxel (RP56976) in patients with metastatic or locally advanced breast cancer
10923 Taxol versus Doxorubicin as first line chemotherapy in advanced breast cancer: A randomized phase II study with crossover
10921 A multicentre randomized phase III study of dose-intensive chemotherapy as primary treatment in a multimodality approach for locally advanced inflammatory breast cancer
10922 A phase II second line chemotherapy study with taxotere (RP56976) given as a one-hour infusion day 1, day 8 repeated every 3 weeks in patients with breast carcinoma
16921B Phase II trial with Taxotere in patients with breast cancer
04924 A phase II first line chemotherapy study with taxotere (RP56976) in patients with metastatic or locally advanced breast cancer
04911 Phase I study of bone marrow protection by ethyol (amifostine) in patients with solid tumors treated with carboplatin
10912 Open phase II study of the nonsteroidal aromatase inhibitor, R 83 842 in postmenopausal women with advanced breast cancer (second line treatment).
16902B Phase II trial of Elsamitrucin (BMY 28090) in patients with advanced breast cancer
10901 Randomized phase III study of adjuvant chemotherapy followed by adjuvant Tamoxifen versus nil for patients with operable breast cancer
10902 Randomized phase III study comparing short, intensive preoperative combination chemotherapy with similar therapy given post-operatively
16893B Phase II trial of GR63178A in patients with advanced breast cancer
16892B Phase II trial of 4'-iodo-4'-deoxydoxorubicin in patients with advanced breast cancer
22881 Phase III study in the conservative management of breast carcinoma by tumorectomy and radiotherapy: assessment of the role of a booster dose of radiotherapy (Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Breast Cancer Cooperative Group)
10832 Phase III trial on the comparison between the alternative and sequential administration of three non-cross-resistant chemotherapy regimens ( CMF, ADM-DBD, CDDP-VDS ), in combination with Tamoxifen in advanced breast cancer.
10881 Randomized phase III study of LHRH-agonist versus LHRH-agonist plus Tamoxifen versus Tamoxifen alone in the treatment of premenopausal advanced breast cancer
16871B Phase II study of duP 785 (NSC 368390) in patients with advanced breast cancer
10873 Phase II trial of breast conserving therapy in women with Paget's disease of the nipple
04872 Randomized pilot study of idarubicin per os (4-dmDNR-IMI 30) in advanced breast cancer. Evaluation/comparison of leukopenia. Comparaison des deux modes d'administration dans les cancers avancés du sein.
10863 Phase III study of continuous Tamoxifen versus intermittent Tamoxifen versus alternating Tamoxifen and MPA. First line endocrine therapy for postmenopausal patients with advanced breast cancer.
16864A Phase II Chemotherapy with Flavone Acetic Acid in Patients with Advanced Breast Cancer Resistant to Conventional Chemotherapy and Hormonal Therapy (Summary Last Modified 03/88)
10861 Randomized phase III trial of second line endocrine treatment of postmenopausal patients with advanced breast cancer
10854 Phase III trial of perioperative adjuvant chemotherapy in Breast Cancer
10853 Phase III trial of radiation therapy vs no treatment for patients with in situ ductal carcinoma of the breast (Jointly with the EORTC Radiotherapy Cooperative Group)
10852 Phase III trial of short versus long term chemotherapy with CMF in postmenopausal patients with advanced breast cancer.
16841B Phase II Chemotherapy with Menogaril in Patients with Advanced Breast Cancer
04832 Phase II Chemotherapy with 4-Demethoxydaunorubicin for Lymphoma (Summary Last Modified 05/88)
1312 A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer
1408 Aiming to Understand the MOlecular Aberrations in Metastatic Breast Cancer

Impressum                               Zuletzt geändert am 18.10.2014 14:16